Shanghai Henlius Biotech, Inc. Class H
About
68.50HKD+5.20 +8.21%
Closed • Updated at 04:37 GMT+00:00Market Cap$4.39B
P/E Ratio41.67
Volume2.43M
Beta0.34
RSI44.08
Gross Margin74.05%
Shanghai Henlius Biotech, Inc. Class H — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 29 2026
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
Feb 5 2026
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 16 2026
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
Dec 23 2025
Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
Nov 20 2025
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
Recent Videos
Henlius (2696 HK): Circ Out. 22nd Jan H-Class Meeting
Dec 24, 2024
Community Chat
Ask AI
Try asking